Omeros (OMER) Share-based Compensation (2010 - 2026)
Omeros' (OMER) quarterly Share-based Compensation came in at $1.9 million in Q1 2026, up 82.34% year-on-year from $1.0 million in Q1 2025, and up 9.0% quarter-over-quarter from $1.7 million in Q4 2025.
Omeros (OMER) Share-based Compensation (2010 - 2026) Analysis & Trends
Omeros has disclosed Share-based Compensation across 17 years of filings, most recently posting $1.9 million for Q1 2026.
- Share-based Compensation for Q1 2026 came in at $1.9 million, up 82.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.6 million (down 27.86% YoY), and the FY2025 annual result was $8.2 million, down 21.93% from the prior year.
- Share-based Compensation came in at $1.9 million for Q1 2026 at Omeros, up from $1.7 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $3.9 million in Q1 2022 to a low of $856000.0 in Q3 2025.
- The 5-year median for Share-based Compensation is $2.7 million (2024), against an average of $2.5 million.
- Across the five-year window, Share-based Compensation tumbled 67.59% in 2025 and surged 82.34% in 2026, its largest moves.
- Omeros' Share-based Compensation stood at $3.3 million in 2022, then decreased by 17.56% to $2.7 million in 2023, then fell by 9.85% to $2.4 million in 2024, then slipped by 28.57% to $1.7 million in 2025, then climbed by 9.0% to $1.9 million in 2026.
- The last three Share-based Compensation figures came in at $1.9 million (Q1 2026), $1.7 million (Q4 2025), and $856000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Omeros | 737.87 Mn | 602.55 Mn | 9.31 Mn | 1.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.89 Mn |
| Mar 31, 2026 | 1.89 Mn |
| Dec 31, 2025 | 1.73 Mn |
| Dec 31, 2025 | 1.73 Mn |
| Sep 30, 2025 | 856,000.00 |
| Sep 30, 2025 | 856,000.00 |
| Jun 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 1.15 Mn |
| Mar 31, 2025 | 1.04 Mn |
| Mar 31, 2025 | 1.04 Mn |
| Dec 31, 2024 | 2.43 Mn |
| Dec 31, 2024 | 2.43 Mn |
| Sep 30, 2024 | 2.64 Mn |
| Sep 30, 2024 | 2.64 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Mar 31, 2024 | 2.66 Mn |
| Mar 31, 2024 | 2.66 Mn |
| Dec 31, 2023 | 2.69 Mn |
| Dec 31, 2023 | 2.69 Mn |